The CMS BALANCE Model launched its Medicaid GLP-1 coverage track on May 1, 2026 — the first time state Medicaid programs have a federally-coordinated path to cover semaglutide, tirzepatide, and orforglipron for weight loss. The Medicare Part D portion that was supposed to follow was delayed on April 21 after insurer pushback, with the existing Medicare GLP-1 Bridge program extended through 2027 in its place.
Research-context information only. Peptides discussed below are research compounds. Protocols, doses, and reactions reported come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
For most cash-paying readers, the headline matters less than the math: who actually gets covered, and what does that mean for compounded GLP-1 pricing? Here is the breakdown.
What Launched on May 1
The BALANCE Model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — is a voluntary CMS Innovation Center test that lets state Medicaid agencies cover GLP-1 medications for weight management at federally-negotiated prices. The Medicaid component opened for enrollment May 1, 2026, with state applications accepted on a rolling basis through July 31, 2026 and implementation continuing through January 2027.
Three pieces have to line up for a Medicaid beneficiary in any given state to get coverage:
- Their state Medicaid agency has to join the model — voluntary and not yet announced state-by-state.
- The state has to sign supplemental rebate agreements with each participating manufacturer (Novo Nordisk, Eli Lilly, others) reflecting CMS-negotiated pricing.
- The patient has to clear prior authorization — typically a BMI threshold plus documented obesity-related comorbidity, plus enrollment in the model's required lifestyle support program.
CMS has not published the list of participating states as of May 2. Expect the early adopters to be states with existing weight-management coverage frameworks; non-expansion states and those that have historically excluded weight-loss drugs from Medicaid formularies are less likely to opt in.
The Medicare Part D portion is a different story. On April 21, CMS announced Part D would not launch in 2027 as planned. Plans cited two concerns: GLP-1s for weight loss have never been covered under Part D, so there is no claims data to model utilization or price competitive bids. And opting in raises adverse selection risk — plans that participate likely attract a disproportionate share of GLP-1 seekers, raising costs.
In place of Part D BALANCE, CMS extended the existing Medicare GLP-1 Bridge through December 31, 2027. Under the Bridge, eligible Part D beneficiaries pay $50 per month for GLP-1s regardless of which phase of the Part D benefit they're in. Manufacturers supply the drug at a net $245 per monthly supply, with CMS covering the $195 difference.
What's Covered (and What Isn't)
Both programs cover the same approved branded products:
| Drug | Brand | Manufacturer | Form | Covered |
|---|---|---|---|---|
| Orforglipron | Foundayo | Eli Lilly | Oral, all doses | Yes (Bridge July 1; BALANCE Medicaid May 1 onward) |
| Semaglutide | Wegovy | Novo Nordisk | Injectable, all doses | Yes |
| Tirzepatide | Zepbound | Eli Lilly | Injectable, KwikPen formulation only | Yes |
| Compounded semaglutide | n/a | 503A/503B pharmacies | Various | No — branded products only |
| Compounded tirzepatide | n/a | 503A/503B pharmacies | Various | No — branded products only |
| Research-grade peptides | n/a | Peptide vendors | Lyophilized | No — separate market |
Branded retatrutide is not approved yet, so it is not covered by either program. Lilly's NDA submission is anchored on TRIUMPH-1 and TRIUMPH-2 readouts expected in 2026, with realistic approval in late 2026 or 2027.
The compounded GLP-1 supply chain — both 503A patient-specific compounding and the broader research-grade peptide market — sits entirely outside these coverage programs. That is not an accident. CMS pricing models are designed to move volume to FDA-approved branded products. The recent FDA 503B exclusion proposal for semaglutide, tirzepatide, and liraglutide is the supply-side companion to BALANCE's demand-side push.
What This Means for You
The decision tree depends entirely on your insurance status and where you live. Walk through it:
If you're on Medicaid in a state that joins BALANCE: This is the cleanest win. Once your state opts in and signs rebate agreements (likely Q3 2026 for early adopters), branded Wegovy, Zepbound, or Foundayo at Medicaid copay rates becomes a real option, assuming you clear the BMI/comorbidity prior auth. The required lifestyle program is structured but not punitive.
If you're on Medicare Part D: Mark July 1, 2026 — that's when the GLP-1 Bridge opens for eligible beneficiaries at $50/month for branded Wegovy, Zepbound KwikPen, or Foundayo. Your provider files prior authorization attesting BMI and comorbidity criteria. The Bridge runs through December 31, 2027.
If you're commercially insured: Nothing here changes for you directly. Manufacturer savings cards on Wegovy and Zepbound continue to drop branded copays as low as $25/month with eligible commercial coverage. Foundayo is on a similar track.
If you're uninsured, underinsured, or in a non-participating Medicaid state: This is the population where the cost gap stays wide. Branded cash-pay through LillyDirect or NovoCare runs $349-$499/month at maintenance dose. Research-grade compounded equivalents from vetted peptide vendors run $80-$180/month for semaglutide and $150-$350/month for tirzepatide. The math that has driven the compounded GLP-1 market for the last three years has not changed for you.
The cost spread between branded and research-grade peptides is the single biggest variable in this market. We track current pricing across recommended vendors on the best semaglutide vendors page and best tirzepatide vendors page, with active coupons listed on the deals page.
